---
title: 'An arms-race against resistance: leukemic stem cells and lineage plasticity'
date: '2024-02-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38375990/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240220170715&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Acute myeloid leukemia (AML) therapy is undergoing rapid development,
  but primary and acquired resistance to therapy complicates the prospect of a durable
  cure. Recent functional and single-cell multi-omics approaches have greatly expanded
  our knowledge of the diversity of lineage trajectories in AML settings. AML cells
  range from undifferentiated stem-like cells to more differentiated myeloid or megakaryocyte/erythroid
  cells. Current clinically relevant drugs predominantly target the ...
disable_comments: true
---
Acute myeloid leukemia (AML) therapy is undergoing rapid development, but primary and acquired resistance to therapy complicates the prospect of a durable cure. Recent functional and single-cell multi-omics approaches have greatly expanded our knowledge of the diversity of lineage trajectories in AML settings. AML cells range from undifferentiated stem-like cells to more differentiated myeloid or megakaryocyte/erythroid cells. Current clinically relevant drugs predominantly target the ...